ZGNX Key Statistics, Chart & Performance
The current stock price of ZGNX is 26.68 null. In the past month the price increased by 2.22%. In the past year, price increased by 28.64%.
ZGNX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZGNX. When comparing the yearly performance of all stocks, ZGNX is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
ZGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZGNX. ZGNX may be in some trouble as it scores bad on both profitability and health.
ZGNX Financial Highlights
Over the last trailing twelve months ZGNX reported a non-GAAP Earnings per Share(EPS) of -4.07. The EPS decreased by -5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -278.4% | ||
| ROA | -48.54% | ||
| ROE | N/A | ||
| Debt/Equity | 0.88 |
ZGNX Forecast & Estimates
15 analysts have analysed ZGNX and the average price target is 37.3 null. This implies a price increase of 39.82% is expected in the next year compared to the current price of 26.68.
For the next year, analysts expect an EPS growth of 26.75% and a revenue growth 113.18% for ZGNX
ZGNX Ownership
About ZGNX
Company Profile
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
Company Info
ZOGENIX INC
5959 Horton St Ste 500
Emeryville CALIFORNIA 94608 US
CEO: Stephen J. Farr
Employees: 218
Phone: 15105508300.0
ZOGENIX INC / ZGNX FAQ
What does ZOGENIX INC do?
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
What is the stock price of ZOGENIX INC today?
The current stock price of ZGNX is 26.68 null. The price increased by 1.6% in the last trading session.
What is the dividend status of ZOGENIX INC?
ZGNX does not pay a dividend.
What is the ChartMill rating of ZOGENIX INC stock?
ZGNX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ZGNX stock?
15 analysts have analysed ZGNX and the average price target is 37.3 null. This implies a price increase of 39.82% is expected in the next year compared to the current price of 26.68.
Should I buy ZGNX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZGNX.